M&A - Kronos Bio, Inc.

Form Type: 10-K

Filing Date: 2025-03-18

Corporate Action: Acquisition

Type: Update

Accession Number: 000174183025000009

Filing Summary: Kronos Bio, Inc. has undergone significant changes as of its latest filing. In November 2024, the company announced a comprehensive review of strategic alternatives aimed at maximizing stockholder value. This evaluation includes pursuing potential acquisitions, mergers, business combinations, or divesting some of the Company's preclinical assets. A substantial workforce reduction of approximately 83% was also implemented to conserve capital. Furthermore, the company has discontinued its clinical trial for istisociclib (KB-0742) due to adverse events and concluded that the product’s development is not justified at this time. The company remains focused on exploring various strategic options, although there is no guaranteed outcome from this strategic review and no timeline has been set for its completion. With the board's possible pursuit of liquidation if no transaction is realized, the company's future actions remain uncertain and contingent upon these evaluations.

Document Link: View Document